


Time (weeks)	Etanercept			Adalimumab			Ustekinumab		
	Mean	SD	N	Mean	SD	N	Mean	SD	N
0	14.1	8.6	287	10.9	5.9	343	12.6	7.5	276
6	8.9	6.1	278	6.9	4.8	315	7.5	5.2	249
12	6.3	4.6	258	5.2	4.8	295	5.3	4.7	237
26	5.2	5.2	218	4.1	4.8	254	3.8	4.5	211
39	5.3	5.1	184	3.4	4.4	211	3.4	4.0	196
52	5.2	4.2	178	3.2	3.2	180	3.4	3.2	158
Time (weeks)	Secukinumab			Ixekizumab			Guselkumab		
	Mean	SD	N	Mean	SD	N	Mean	SD	N
0	10.3	7.0	75	8.4	6.6	55	10.9	6.6	44
6	5.5	4.5	67	4.0	3.9	51	5.8	3.8	36
12	3.8	3.4	63	2.4	2.7	45	4.0	3.0	31
26	4.6	4.6	49	2.5	3.3	40	3.5	3.0	29
39	4.0	4.3	48	2.6	3.5	31	2.4	2.4	24
52	4.1	3.6	38	2.4	2.8	28	2.5	2.7	20

Fig. S1. Mean Psoriasis Area and Severity Index (PASI) values per biologic from baseline until 1 year of treatment, uncorrected for confounders.



**Fig. S2. One-year PASI75 percentages based on the mixed logistic regression model, corrected for baseline Psoriasis Area and Severity Index (PASI), body weight and biologic naivety.** Visualizations were made for patients with average [AQ2] characteristics (baseline PASI 12.0, body weight 90 kg), and split for biologic-naïve and non-naïve treatment episodes (TEs).